Avalon Globocare CORP 8-K filings

Avalon GloboCare's Laboratory Services MSO has launched a direct-to-consumer DNA test in the U.S. to assess an individual's genetic predisposition to opioid dependence.

Avalon GloboCare has officially launched online sales of its KetoAir breathalyzer in the U.S., featuring AI-powered nutritional recommendations.

Avalon GloboCare Corp. has dismissed Marcum LLP as its independent auditor and appointed M&K CPAS, PLLC, effective July 10, 2024.

Avalon Globocare Corp. has entered into a securities purchase agreement for $2.845 million in convertible notes, along with warrants and common stock issuances.

Avalon GloboCare Corp. has received a notice from Nasdaq for not filing its quarterly report, putting the company at risk of delisting if compliance is not regained.

Avalon GloboCare Corp. has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement, now until October 28, 2024.

Avalon Globocare Corp. has entered into mortgage and security agreements with Mast Hill Fund L.P. and Firstfire Global Opportunities Fund, LLC to secure a total of $2.7 million in debt.